118 related articles for article (PubMed ID: 7908037)
1. The role of cyclic AMP and phosphodiesterase activity in the mechanism of action of tetramethylpyrazine on human and dog cardiac and dog coronary arterial tissues.
Lin CI; Wu SL; Tao PL; Chen HM; Wei J
J Pharm Pharmacol; 1993 Nov; 45(11):963-6. PubMed ID: 7908037
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Anderson WH; Fitzpatrick DF; Hwang DP; Szentivanyi A
Biochem Pharmacol; 1979 Apr; 28(8):1391-5. PubMed ID: 87201
[No Abstract] [Full Text] [Related]
3. A possible mechanism of action of tetramethylpyrazine on vascular smooth muscle in rat aorta.
Wu CC; Chiou WF; Yen MH
Eur J Pharmacol; 1989 Oct; 169(2-3):189-95. PubMed ID: 2553446
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclic AMP phosphodiesterase by 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)] ethyl ester 5-methyl ester hydrochloride (YC-93), a potent vasodilator.
Sakamoto N; Terai M; Takenaka T; Maeno H
Biochem Pharmacol; 1978; 27(8):1269-74. PubMed ID: 81059
[No Abstract] [Full Text] [Related]
5. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of cyclic AMP and contractile responses to isoprenaline: effects of a dihydropyridine derivative, nicardipine (YC-93), on canine ventricular muscle.
Endoh M; Yanagisawa T; Taira N
Eur J Pharmacol; 1980 Oct; 67(2-3):225-33. PubMed ID: 6257529
[TBL] [Abstract][Full Text] [Related]
7. Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone.
Souness JE; Villamil ME; Scott LC; Tomkinson A; Giembycz MA; Raeburn D
Br J Pharmacol; 1994 Apr; 111(4):1081-8. PubMed ID: 8032594
[TBL] [Abstract][Full Text] [Related]
8. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.
Tanaka T; Ishikawa T; Hagiwara M; Onoda K; Itoh H; Hidaka H
Pharmacology; 1988; 36(5):313-20. PubMed ID: 2841693
[TBL] [Abstract][Full Text] [Related]
9. Coronary vasodilatory, spasmolytic and cAMP-phosphodiesterase inhibitory properties of dihydropyranocoumarins and dihydrofuranocoumarins.
Thastrup O; Fjalland B; Lemmich J
Acta Pharmacol Toxicol (Copenh); 1983 Apr; 52(4):246-53. PubMed ID: 6306994
[TBL] [Abstract][Full Text] [Related]
10. Effects of isoproterenol on active force and Ca2+ X calmodulin-sensitive phosphodiesterase activity in porcine coronary artery.
Miller JR; Wells JN
Biochem Pharmacol; 1987 Jun; 36(11):1819-24. PubMed ID: 3034289
[TBL] [Abstract][Full Text] [Related]
11. Relaxant mechanisms of cyclic AMP-increasing agents in porcine coronary artery.
Yamagishi T; Yanagisawa T; Satoh K; Taira N
Eur J Pharmacol; 1994 Jan; 251(2-3):253-62. PubMed ID: 7512040
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of a high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Szentivanyi A
Biochem Pharmacol; 1982 Nov; 31(21):3403-6. PubMed ID: 6293511
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the cyclic nucleotide phosphodiesterase subtypes involved in the regulation of the L-type Ca2+ current in rat ventricular myocytes.
Verde I; Vandecasteele G; Lezoualc'h F; Fischmeister R
Br J Pharmacol; 1999 May; 127(1):65-74. PubMed ID: 10369457
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.
Bowman P; Haikala H; Paul RJ
J Pharmacol Exp Ther; 1999 Jan; 288(1):316-25. PubMed ID: 9862786
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of vasoconstriction by tetramethylpyrazine: does it act by blocking the voltage-dependent Ca channel?
Kwan CY; Daniel EE; Chen MC
J Cardiovasc Pharmacol; 1990 Jan; 15(1):157-62. PubMed ID: 1688974
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of cardiovascular action of trapidil.
Satoh K; Yamashita S; Endoh M; Taira N
Arzneimittelforschung; 1980; 30(8):1264-8. PubMed ID: 6254546
[TBL] [Abstract][Full Text] [Related]
17. Studies on the inhibition of phosphodiesterase-catalyzed cyclic AMP and cyclic GMP breakdown and relaxation of canine tracheal smooth muscle.
Polson JB; Krzanowski JJ; Fitzpatrick DF; Szentivanyi A
Biochem Pharmacol; 1978 Jan; 27(2):254-6. PubMed ID: 203292
[No Abstract] [Full Text] [Related]
18. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor.
Yu SM; Cheng ZJ; Kuo SC
Eur J Pharmacol; 1995 Jun; 280(1):69-77. PubMed ID: 7498256
[TBL] [Abstract][Full Text] [Related]
19. Vascular effects of tetramethylpyrazine: direct interaction with smooth muscle alpha-adrenoceptors.
Kwan CY; Gaspar V; Shi AG; Wang ZL; Chen MC; Ohta A; Cragoe EJ; Daniel EE
Eur J Pharmacol; 1991 May; 198(1):15-21. PubMed ID: 1680713
[TBL] [Abstract][Full Text] [Related]
20. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
